Synthesis of 6-Dialkylaminoalkylamino Pyrano[2,3-c]Acridones and Benzo[b]Pyrano[3,2-h]Acridones: Soluble Acronycine Analogues With Increased Cytotoxic Activity
The novel 6-dialkylaminoalkylamino-3,3,12-trimethyl-3,12-dihydro-7H-pyrano[2,3-c ]acridine-7-ones 5–11 and their benzo [b]pyrano[2,3-h]acridine-7-one counterparts 12–18 were prepared by treatment of acronycine (1) or benzo[b]acronycine (4) with an excess of the appropriate dialkylaminoalkylamine. In both series, the introduction of a dialkylaminoalkylamino side chain at position 6 resulted in a significant increase of the cytotoxic activity against L1210 cells when compared with the parent compounds bearing a methoxy group, accompanied with an increased potency to arrest cells in the G2 + M phases of the cell cycle.
Document Type: Research Article
Affiliations: 1: *Laboratoire de Pharmacognosie de l'Université René Descartes, U.M.R./C.N.R.S. No. 8638, Faculté des Sciences Pharmaceutiques et Biologiques, 4, Avenue de l'Observatoire, F-75006 Paris, France 2: †Laboratoire de Pharmacognosie de l'Université de Rouen-Haute Normandie, Faculté de Pharmacie, 22, Boulevard Gambetta, F-76183 Rouen Cedex, France 3: ‡Les Laboratoires Servier, 1 rue Carle Hébert, F-92415 Courbevoie Cedex, France 4: §Institut de Recherche Servier, 11 rue des Moulineaux, F-92150 Suresnes, France
Publication date: 2002-01-01
- Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.